1-1 of 1
Keywords: Real-life cohort
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey

Available to Purchase
Subject Area:
Gastroenterology
Stephan R. Vavricka, Milos Spasojevic, Gerhard Rogler, Alain M. Schoepfer, Frank Seibold, Jan Borovicka, Pascal Frei, Jonas Zeitz, Thomas Greuter, Christine Manser, Michael Scharl, Benjamin Misselwitz, Alex Straumann, Pierre Michetti, Luc Biedermann, for the Swiss IBDnet
Journal: Digestive Diseases
Dig Dis (2017) 35 (5): 423–432.
https://doi.org/10.1159/000475494
Published Online: 09 June 2017
... efficacy Real-life cohort Fig. 3 a-c Evolution of HBI during CZP treatment according to subgroups. Box plots of HBI values at the different times of follow-up are depicted (with black lines as mean values) for anti-TNF experienced vs. naïve ( a ) patients, patients previously treated with 1...
View articletitled, Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
Open the PDF for Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey in another window